Medimmune stops arthritis and psoriasis trials

By Staff Writers
Tuesday, 31 August, 2004

Maryland-based MedImmune has halted the clinical trials of its Vitaxin drug for rheumatoid arthritis and psoriasis, blaming a lack of benefits seen with the experimental treatment.

The drug maker said no safety issues came up during the trial. It will continue to study the compound to treat cancer.

SEQ koala population carries immunity to retrovirus

Koalas from a population north of the Brisbane River appear to have evolved a unique genomic...

RSV immunisation program for babies slashes hospital stays

An Australian-first study has demonstrated the effectiveness of immunisation against respiratory...

A targeted treatment option for psoriasis

New research from MedUni Vienna paves the way for the development of a therapy that not only...

Content from other channels on our network

Western Sydney Local Health District prosecution withdrawn

Bankstown-Lidcombe and Liverpool Hospitals trial body cameras

Brain and kidney injury treatment after cardiac surgery

Thousands of NSW public hospital doctors to strike next week

Gentle care practices to help reduce pressure injury risk factors

Canadian Solar and Flow Power to install anti-hail solar

Wannon Water solves pump blockage issue

STABILISOR tech revolutionises air compressor operation

Kate Ceberano helps raise over $580,000 for clean water

Consult Australia Awards — winners announced

Aranet supermarket temperature monitoring solution

Norco's fresh full cream milk wins Canstar Blue award

Visy trials its new recyclable fibre-based thermal insulation

What's new on the shelf: new food products for Easter

Hygienic design for food production automation systems